Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
about
Pediatric Statin Administration: Navigating a Frontier with Limited DataRosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 CellsMembrane transporters in drug developmentDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteersIdentification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substratesXenobiotic, bile acid, and cholesterol transporters: function and regulation.Environmental and genetic factors affecting transport of imatinib by OATP1A2Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5.Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Interactions of green tea catechins with organic anion-transporting polypeptides.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Pharmacokinetics of mangiferin and its metabolite-Norathyriol, Part 1: Systemic evaluation of hepatic first-pass effect in vitro and in vivo.The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Improving the prediction of the brain disposition for orally administered drugs using BDDCS.What do drug transporters really do?Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Drug-drug interaction studies: regulatory guidance and an industry perspectiveDownregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug InteractionsHepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytesHepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineGenetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Transporter pharmacogenetics and statin toxicity.Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.Efflux and uptake transporters as determinants of statin response.Drug transport by breast cancer resistance protein.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Transporter-mediated drug-drug interactions.
P2860
Q28068014-8FDDFFE5-E9CC-47F0-A1D4-0EE373C936ECQ28550796-EDE2C957-1C14-4C0C-BA25-6F0F3EF0B461Q29616802-B45D81E3-2770-4182-A583-1CD27A842E31Q30364846-18657837-955B-4063-88B8-B62AA6630587Q33581531-A4A6F5DC-EBAE-49A5-A025-EB08BA05D212Q33686542-0615A302-4873-497D-9DD8-DDAA148B80A9Q33686976-C3357A1E-93B9-4198-8AB9-18142D4E4443Q33714593-F88E4DB8-3BAF-452B-8A8E-DC79352C7447Q33878471-B9F69037-54E7-48C6-B0B4-289F79BFF2D3Q33994570-4867A835-A23B-4E3A-99FA-D5C8AABE33F3Q34023028-5A67D444-01F6-4457-8F62-05D69143B92EQ34079760-EED8C818-18E6-4131-84A2-405F0E011930Q34360004-B8515347-E260-4B6C-B460-7FDD222DC335Q34571070-45385F61-994E-4286-8810-FD5E2D5A3014Q34680467-3B599D39-6888-407B-8531-D5CFDF3263DCQ34856952-E3B60E64-200D-4D00-AEC9-DEF9F720DA70Q34871636-5EE6328C-8331-4675-ABEB-FC59A2EF4E3BQ36003898-DF95A015-D9E1-42B3-872C-FF0AA903EF16Q36020304-A2132C01-9018-4DA8-99E0-AEA64FCAB549Q36233941-9159C2BA-DDA4-4C65-9007-E1E25C7AB62BQ36394062-42CEF575-90AA-4762-A09F-6CFA22520E16Q36571217-0D7B8510-32BC-467E-8ADE-7EDB80120F60Q36776621-B0CB710E-38B8-4AAA-9560-F0169113B04CQ36951933-3C012BC2-3F7A-43F2-A1CD-D36D2C1BA095Q37145705-2B2DC4C0-6258-4F1F-B7DD-A5DF2191175CQ37331801-C512456A-E549-441C-8F76-D1762233C3D3Q37331821-EF26FDDE-4004-4F3B-8136-CE716335EE47Q37394474-3EA9B65E-9CFF-4EF9-82C0-8AA6AE4D0EEEQ37399440-2225085A-C25D-43FA-9C4A-AFDF98E2C7A1Q37470663-59790DB8-C95C-4635-B7A8-E5452F402BFDQ37481450-406A2334-29B3-43FD-A67F-314F3FFF04D1Q37627544-20A157DF-613C-4EED-8BA0-7C31391A4608Q37650803-CF06E5FC-4EE5-4C10-9886-78F2C0B6FDB3Q37714185-214F4CCF-AC69-4BB6-ACFC-87168AD3354DQ37724381-C9460982-C26F-414C-AB26-171D4FE7A39DQ37793056-0FC1FBBB-4566-4012-AF8E-FC46347C4BD2Q37810986-D6B3F439-54AD-4FC6-9D71-FD67AE3314EFQ37841614-DEE673A4-27CA-4113-BD43-88421F88F4C8Q37855801-E107B20A-3A61-4F04-86F5-0EAAC3EFEFDBQ37905033-F2696D87-5389-494B-B535-CD05642366EE
P2860
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@en
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@nl
type
label
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@en
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@nl
prefLabel
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@en
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@nl
P2093
P356
P1476
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
@en
P2093
Kazuya Maeda
Satoshi Kitamura
Yuichi Sugiyama
P304
P356
10.1124/DMD.108.021410
P577
2008-07-10T00:00:00Z